Zomedica Corp. (ZOM)
USD 0.1
(-0.21%)
USD 0.1
(-0.21%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -29.38 Million USD | -91.6% |
| 2023 | -15.33 Million USD | 23.4% |
| 2022 | -19.57 Million USD | -22.43% |
| 2021 | -16.38 Million USD | 14.67% |
| 2020 | -18.99 Million USD | -16.39% |
| 2019 | -16.44 Million USD | -104.51% |
| 2018 | -7.97 Million USD | -34.26% |
| 2017 | -5.96 Million USD | -160.55% |
| 2016 | -2.27 Million USD | -5274.19% |
| 2015 | -42.4 Thousand USD | 45.27% |
| 2014 | -77.49 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -5.94 Million USD | 80.21% |
| 2024 Q4 | -9.51 Million USD | -2573.37% |
| 2024 Q1 | -4.73 Million USD | -81.49% |
| 2024 Q2 | -3.81 Million USD | 20.34% |
| 2024 FY | - USD | -66.55% |
| 2023 FY | - USD | 23.4% |
| 2023 Q3 | -5.37 Million USD | -7.64% |
| 2023 Q2 | -4.99 Million USD | -43.06% |
| 2023 Q1 | -3.48 Million USD | 27.2% |
| 2023 Q4 | -1.33 Million USD | 75.16% |
| 2022 Q2 | -5.13 Million USD | -38.36% |
| 2022 Q4 | -4.79 Million USD | 22.8% |
| 2022 FY | - USD | -22.43% |
| 2022 Q1 | -3.71 Million USD | 7.08% |
| 2022 Q3 | -6.2 Million USD | -20.79% |
| 2021 FY | - USD | 14.67% |
| 2021 Q2 | -5.17 Million USD | -139.33% |
| 2021 Q1 | -2.16 Million USD | 18.44% |
| 2021 Q4 | -3.99 Million USD | 17.66% |
| 2021 Q3 | -4.85 Million USD | 6.29% |
| 2020 Q2 | -2.19 Million USD | 80.89% |
| 2020 FY | - USD | -16.39% |
| 2020 Q4 | -2.65 Million USD | -0.26% |
| 2020 Q3 | -2.64 Million USD | -20.61% |
| 2020 Q1 | -11.48 Million USD | -37.38% |
| 2019 Q1 | -2.13 Million USD | 14.64% |
| 2019 FY | - USD | -104.51% |
| 2019 Q4 | -8.35 Million USD | -393.63% |
| 2019 Q3 | -1.69 Million USD | 58.93% |
| 2019 Q2 | -4.12 Million USD | -93.47% |
| 2018 Q1 | -1.83 Million USD | 37.41% |
| 2018 Q3 | -2.06 Million USD | -31.69% |
| 2018 Q4 | -2.49 Million USD | -20.74% |
| 2018 FY | - USD | -34.26% |
| 2018 Q2 | -1.57 Million USD | 14.59% |
| 2017 Q1 | -15.55 Thousand USD | 34.84% |
| 2017 Q3 | -1.02 Million USD | 3.49% |
| 2017 Q2 | -1.06 Million USD | -6724.29% |
| 2017 Q4 | -2.93 Million USD | -186.65% |
| 2017 FY | - USD | -160.55% |
| 2016 Q1 | -15.6 Thousand USD | -77.77% |
| 2016 Q4 | -23.87 Thousand USD | -400.88% |
| 2016 Q3 | -4766.69 USD | 57.23% |
| 2016 FY | - USD | -5274.19% |
| 2016 Q2 | -11.14 Thousand USD | 28.59% |
| 2015 Q2 | -7895.27 USD | -34.8% |
| 2015 Q4 | -8779.16 USD | 20.97% |
| 2015 Q3 | -11.1 Thousand USD | -40.7% |
| 2015 FY | - USD | 45.27% |
| 2015 Q1 | -5857.02 USD | 88.46% |
| 2014 Q2 | -14.5 Thousand USD | 0.0% |
| 2014 Q4 | -50.74 Thousand USD | -640.24% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | -6855.44 USD | 52.75% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| China Pharma Holdings, Inc. | 8436.00 USD | 348452.3% |
| cbdMD, Inc. | -7.46 Million USD | -293.516% |
| cbdMD, Inc. | -7.46 Million USD | -293.516% |